Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

D2975000

Doxorubicine hydrochloride

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

DOX, Hydroxydaunorubicine hydrochloride

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C27H29NO11 · HCl
Numéro CAS:
Poids moléculaire :
579.98
Numéro Beilstein :
4229251
Numéro CE :
Numéro MDL:
Code UNSPSC :
41116107
ID de substance PubChem :
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

doxorubicin

Fabricant/nom de marque

EDQM

Pf

216 °C (dec.) (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

Cl[H].COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO

InChI

1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1

Clé InChI

MWWSFMDVAYGXBV-RUELKSSGSA-N

Informations sur le gène

human ... TOP2A(7153)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets, has been developed and issued under the Authority of the Issuing Pharmacopoeia.

For further information and support please go to the website of the issuing Pharmacopoeia.

Produced by certain strains of Streptomyces coeruleorubidus or Streptomyces peucetius or obtained by any other means.

Application

This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia. Their suitability for any other use is not guaranteed and is the sole responsibility of the user. This standard is not intended for human or animal use.
Established for the preparation of the below-given solutions as per European Pharmacopoeia:
  • Reference solutions (b) and (c) in the testing of related substances in daunorubicin hydrochloride using liquid chromatography (General text 2.2.29), according to the monograph 0662
  • Reference solutions (a) and (c) to test related substances in doxorubicin hydrochloride using liquid chromatography (General text 2.2.29), according to the monograph 0714
  • Reference solutions (b) and (c) in the testing of related substances in epirubicin hydrochloride using liquid chromatography (General text 2.2.29), according to the monograph 1590

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Pictogrammes

Health hazardExclamation mark

Mention d'avertissement

Danger

Mentions de danger

Classification des risques

Acute Tox. 4 Oral - Carc. 1B - Muta. 1B - Repr. 1B

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Daunorubicin hydrochloride
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 2343-2344 (2008)
Maide Gökçe Bekaroğlu et al.
Materials science & engineering. C, Materials for biological applications, 103, 109838-109838 (2019-07-28)
The objective of the study was to obtain multifunctional core shell nanostructures of superparamagnetic iron oxide nanoparticles (Fe3O4) coated with various ionic biopolymers that can optimize toxicity to healthy cells, colloidal instabilities and drug loading capacities. These nanostructures can also
Xin Ma et al.
Proceedings of the National Academy of Sciences of the United States of America, 111(17), 6389-6394 (2014-04-16)
A critical challenge for chemotherapy is the development of chemoresistance in breast cancer. However, the underlying mechanisms and validated predictors remain unclear. Extracellular vesicles (EVs) have gained attention as potential means for cancer cells to share intracellular contents. In adriamycin-resistant
C Main et al.
Health technology assessment (Winchester, England), 10(9), 1-132 (2006-03-21)
To examine the clinical effectiveness and cost-effectiveness of intravenous formulations of topotecan monotherapy, pegylated liposomal doxorubicin hydorocholoride (PLDH) monotherapy and paclitaxel used alone or in combination with a platinum-based compound for the second-line or subsequent treatment of advanced ovarian cancer.
Shuai Li et al.
Journal of biomedical nanotechnology, 10(8), 1480-1489 (2014-07-16)
Amphiphilic copolymers have been paid much attention for controlled drug release for many years due to their obvious advantages. In this study, an acid-triggered drug carrier system capable of rapid intracellular drug release is investigated for potential tumor therapy. The

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique